Δημοσίευση στις Apr 2018 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/29459079/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=114
Curr Opin Pharmacol
Search in PubMed
Search in NLM Catalog
Add to Search
Peripheral artery disease (PAD) affects more than 200 million people worldwide. Hypertension has been related to increased risk of PAD. The treatment of elevated blood pressure (BP) in these patients is indicated to lower the cardiovascular risk with a BP goal of less than 130/80mmHg. Although there is no evidence that one class of antihypertensive medication or strategy is superior for BP lowering in PAD, the use of renin-angiotensin-system (RAS) inhibitors can be effective to reduce the cardiovascular risk. Beta-blockers (BBs) are not contraindicated. In the presence of carotid atherosclerosis, calcium-channel blockers (CCBs) and angiotensin-converting-enzyme inhibitors are recommended. In fibromuscular dysplasia the treatment of choice is percutaneous renal angioplasty. In renal artery disease optimal medical therapy includes RAS inhibitors, CCBs, BBs and diuretics.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Beta-blockers for hypertension.
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
Cochrane Database Syst Rev. 2007.
Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Am J Ther. 2017 Jan/Feb;24(1):e68-e80. doi: 10.1097/MJT.0000000000000369.
Am J Ther. 2017.
Renal protection in hypertensive patients: selection of antihypertensive therapy.
Drugs. 2005;65 Suppl 2:29-39. doi: 10.2165/00003495-200565002-00005.
The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
Dan Med J. 2012 Sep;59(9):B4514.
Dan Med J. 2012.
Trends in antihypertensive treatment–lessons from the National Acute Stroke Israeli (NASIS) registry.
Blood Press. 2014 Oct;23(5):262-9. doi: 10.3109/08037051.2013.876771. Epub 2014 Feb 3.
Blood Press. 2014.
PubMed Central articles
Inhibitors of G12C Mutant Ras Proteins for the Treatment of Cancers.
ACS Med Chem Lett. 2018 Dec 10;10(1):10-11. doi: 10.1021/acsmedchemlett.8b00576. eCollection 2019 Jan 10.
ACS Med Chem Lett. 2018.
Free PMC article.
No abstract available..